Diabetes is one of the most common chronic diseases worldwide, with more than 74 million people suffering from it in Europe alone, according to the World Health Organization. To meet this challenge and promote innovation in diabetes treatment, the European Union Innovation Fund Horizon 2020 has funded a project called ENLIGHT, which aims to develop a "pancreas living model (i.e., organ chip) " for drug testing by combining 3D bioprinting technology and advanced biomaterials . The project brings together top teams from academia, industry, and research institutions, and will start in 2021 and last until April 2025. Antarctic Bear will delve into the background of the ENLIGHT project, technical details, and its impact on the future of medicine.
The core goal of the ENLIGHT project is to use 3D bioprinting technology to develop a living pancreas model for drug testing. This "organ chip" can simulate the function of the human pancreas and help pharmaceutical companies quickly screen and optimize diabetes drugs in the early stages. Compared with traditional animal experiments or clinical trials, this technology can significantly shorten the drug development cycle and significantly reduce R&D costs. In recent years, the continued rise in pharmaceutical costs has become one of the main reasons for the rise in medical costs. The technological breakthroughs of the ENLIGHT project are expected to alleviate this problem.
This research is not limited to drug testing. If the experiment is successful, it may be possible to print functional pancreatic tissue directly in the patient's body in the future, thus providing a new treatment method for diabetic patients. Once this technology matures, it will completely change the pattern of diabetes treatment and bring hope to millions of patients.
The success of the ENLIGHT project is inseparable from the joint efforts of top experts and institutions in multiple fields. The project brings together academic institutions such as the University Medical Center Utrecht, the Federal Institute of Technology in Lausanne, and the Federal Institute of Technology in Zurich, as well as industry leaders such as AstraZeneca, the Gianino Bassetti Foundation, the bioprinting company Readily 3D, and the gelatin expert Rousselot. Each partner plays a key role in its own field, and Rousselot's contribution to the development of biomaterials is particularly outstanding.
In the ENLIGHT project, researchers used an innovative technology called " volume bioprinting ". This technology was developed by the Swiss company Readily 3D. Its core principle is to quickly solidify photosensitive hydrogels into complex structures through three-dimensional light projection . Compared with traditional extrusion bioprinting, volume bioprinting has significant advantages: it can print centimeter-level structures in a few seconds, while avoiding shear force and stress damage to cells, thereby ensuring cell survival and functional stability.
"Speed is key in volumetric bioprinting, as the rapidly cross-linked matrix material allows for a stable structure without damaging suspended cells," explains Jos Olijve, Senior Project Manager at Rousselot. This technology provides the ENLIGHT project with a solid technical foundation, enabling the efficient fabrication of complex pancreatic tissue models.
In addition to advanced printing technology, the choice of biomaterials is also crucial. Rousselot has developed a new hydrogel material called methacrylamide-modified gelatin (GelMA). This material is highly tunable and can simulate different types of tissue environments by adjusting the molecular weight, degree of methacrylate (MA) modification, and concentration.
Olijve added: "GelMA is a very special material that not only mimics the mechanical properties of the natural pancreas, but is also stable at body temperature, which is a key requirement in bioprinting applications." In addition, GelMA has good biocompatibility and photo-crosslinking capabilities, which make it ideal for 3D bioprinting. By optimizing the properties of GelMA, Rousselot provided the ENLIGHT project with a material that can both support cell growth and meet the needs of volumetric bioprinting. For example, by measuring the mechanical strength of porcine pancreatic tissue, the researchers determined the GelMA formula that is most suitable for pancreatic cell growth. This precise matching process ensures that the printed tissue models are highly functional and realistic.
The ENLIGHT project is not only a major breakthrough in biological 3D printing technology, but also marks a new era in diabetes treatment. By combining advanced printing technology and high-performance biomaterials, researchers are gradually making the leap from laboratory to clinic. This will not only help accelerate drug development, but also provide patients with more personalized and efficient treatment options. More importantly, the results achieved by the ENLIGHT project have been highly recognized by the European Commission and listed as a "technology-ready" project. This shows that the project is not only scientifically significant, but also has commercial potential, laying a solid foundation for future medical innovation.
The ENLIGHT project demonstrates the great potential of 3D bioprinting technology in the medical field. From drug testing to functional organ replacements, 3D bioprinting technology is redefining our understanding of disease treatment. With the advancement of more research projects and the continuous optimization of technology, we have reason to believe that 3D bioprinting will become an indispensable part of the future medical field and bring more possibilities to human health!
